Pamela Rama-Depadua, MD
Cardiovascular Disease · Jacksonville Beach, FLNPI 1669474086
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $188,924 of the $227,022 with a category attached, or 83.2%. Novo Nordisk accounts for 89.1% of it on its own, with 44 other manufacturers making up the rest. 2025 is the largest year on record at $60,190, more than ten times the $1,119 reported in 2019. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 706 payments — averaging $321.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$202K
- AstraZeneca$14K
- Amgen$1K
- Pfizer$1K
- Medtronic$981
- Abbott$839
- plus $7K from 39 others
Across 21 payments — averaging $3035.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$64K
What the payments were for
- Consulting fees$9,5474%
- Speaking & faculty fees$188,92483%
- Travel & lodging$12,7196%
- Food & beverage$15,5057%
- Education$3280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$141,491
- Saxenda$37,274
- FARXIGA$13,275
- Ozempic$2,948
- TRICLIP$286
- LINQ II$236
- ONYX FRONTIER$233
- AMPLATZER AMULET$176
- ZIO XT Patch$151
- Zio monitor$151
- NAVITOR$150
- Hillrom - Carnation Ambulatory Monitor$143
- MitraClip$139
- FUROSCIX$125
- UPTRAVI$123
- OPSUMIT$123
- VYNDAQEL$123
- LEQVIO$115
- RYBELSUS$115
- Tresiba$115
How this compares
$227,022 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 583 | $727,794 |
| Repatha SureclickEvolocumab | 249 | $276,462 |
| XareltoRivaroxaban | 151 | $170,281 |
| OzempicSemaglutide | 113 | $129,357 |
| EntrestoSacubitril/Valsartan | 101 | $123,006 |
| MounjaroTirzepatide | 73 | $79,520 |
| FarxigaDapagliflozin Propanediol | 84 | $77,802 |
| JardianceEmpagliflozin | 66 | $57,973 |
| WegovySemaglutide | 28 | $39,816 |
| Praluent PenAlirocumab | 38 | $33,744 |
| Nebivolol Hcl | 358 | $22,881 |
| MultaqDronedarone Hcl | 17 | $18,955 |
| NexletolBempedoic Acid | 17 | $16,856 |
| Repatha SyringeEvolocumab | 14 | $12,488 |
| Bisoprolol Fumarate | 351 | $8,711 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,109 | $727,794583 claims |
| Johnson & JohnsonXarelto | $687 | $170,281151 claims |
| Novo NordiskOzempic, Wegovy | $202,313 | $169,173141 claims |
| NovartisEntresto | $401 | $123,006101 claims |
| Lilly USA, LLCMounjaro | $65 | $79,52073 claims |
| AstraZenecaFarxiga | $13,691 | $77,80284 claims |
| Boehringer IngelheimJardiance | $352 | $57,97366 claims |
| Sanofi-aventis U.S. LLCMultaq | $422 | $18,95517 claims |
| Esperion Therapeutics, Inc.Nexletol | $262 | $16,85617 claims |
| AmgenCorlanor | $1,128 | $6,96212 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $15 | $4,65812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Jacksonville Beach
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.